Radical gastrectomy for D2 distal gastric cancer

Patient＇s information The patient is a 56-year-old man who visited our hospital for ＂repeated epigastric pain for more than two months.＂ Physical examination showed nearly pale appearance; abdomen was soft and no mass palpable; left supraclavicular lymph node （-）; and digital rectal examination （-）.

A comparative study of totally laparoscopic distal gastrectomy versus laparoscopic-assisted distal gastrectomy in gastric cancer patients: Short-term operative outcomes at a high-volume center

Objective： Laparoscopic gastrectomy has been established as a standard treatment for early gastric cancer, and its use is increasing recently. Compared with the conventional laparoscopy-assisted distal gastrectomy （LADG）, totally laparoscopic distal gastrectomy （TLDG） involves intracorporeal reconstruction, which can avoid the additional incision, resulting in pain reduction and early recovery. This study aimed to compare the short-term postoperative outcomes of TLDG vs. LADG in gastric cancer in a high-volume center.Methods： A retrospective cohort study was conducted on 1,322 patients who underwent laparoscopic distal gastrectomy from June 2012 to June 2017 at the National Cancer Center, Korea. LAD G was performed in the early period before July 2015, and TLDG was applied in the later period. Postoperative short-term outcomes were compared in terms of complication and clinical course between the two groups. Pain score was measured by rating the pain intensity from 0 to 10 points on postoperative day （POD） 1 and 3. Results： A total of 667 patients underwent LADG and 655 patients underwent TLDG. Clinieopathologic characteristics were not different in both groups. Intraoperative estimated blood loss （EBL） was significantly lower in the TLDG group （P〈0.001）. Postoperative pain scores were significantly lower in the TLDG group than in the LADG group on POD 1 （5.1±1.5 vs. 4.8±1.4, P=0.015）. First flatus passage after operation was significantly earlier in the TLDG group （3.4±0.8 d vs. 3.2±0.6 d, P〈0.001）. There were no differences in postoperative complications and hospital stay between the two groups. Conclusions： Based on the reported short-term postoperative outcomes, TLDG is safe and feasible as well as LADG. Moreover, compared with LADG, TLDG can reduce intraoperative EBL and postoperative pain and enhance the bowel motility in gastric cancer surgery.

Gastric cancer arising from the remnant stomach after distal gastrectomy:A review

Gastric stump carcinoma was initially reported by Balfore in 1922,and many reports of this disease have since been published. We herein review previous reports of gastric stump carcinoma with respect to epidemiology,carcinogenesis,Helicobacter pylori(H. pylori) infection,Epstein-Barr virus infection,clinicopathologic characteristics and endoscopic treatment. In particular,it is noteworthy that no prognostic differences are observed between gastric stump carcinoma and primary upper third gastric cancer. In addition,endoscopic submucosal dissection has recently been used to treat gastric stump carcinoma in the early stage. In contrast,many issues concerning gastric stump carcinoma remain to be clarified,including molecular biological characteristics and the carcinogenesis of H.pylori infection.We herein review the previous pertinent literature and summarize the characteristics of gastric stump carcinoma reported to date.

Roux-en-Y versus BillrothⅠreconstruction after distal gastrectomy for gastric cancer:A meta-analysis

AIM: To conduct a meta-analysis to compare Roux-en-Y (R-Y) gastrojejunostomy with gastroduodenal Billroth?I?(B-I) anastomosis after distal gastrectomy (DG) for gastric cancer.METHODS: A literature search was performed to identify studies comparing R-Y with B-I?after DG for gastric cancer from January 1990 to November 2012 in Medline, Embase, Science Citation Index Expanded and the Cochrane Central Register of Controlled Trials in The Cochrane Library. Pooled odds ratios (OR) or weighted mean differences (WMD) with 95%CI were calculated using either ?xed or random effects model. Operative outcomes such as operation time, intraoperative blood loss and postoperative outcomes such as anastomotic leakage and stricture, bile re?ux, remnant gastritis, re?ux esophagitis, dumping symptoms, delayed gastric emptying and hospital stay were the main outcomes assessed. Meta-analyses were performed using RevMan 5.0 software (Cochrane library).RESULTS: Four randomized controlled trials (RCTs) and 9 non-randomized observational clinical studies (OCS) involving 478 and 1402 patients respectively were included. Meta-analysis of RCTs revealed that R-Y reconstruction was associated with a reduced bile re?ux (OR 0.04, 95%CI: 0.01, 0.14; P < 0.00?001) and remnant gastritis (OR 0.43, 95%CI: 0.28, 0.66; P = 0.0001), however needing a longer operation time (WMD 40.02, 95%CI: 13.93, 66.11; P = 0.003). Meta-analysis of OCS also revealed R-Y reconstruction had a lower incidence of bile re?ux (OR 0.21, 95%CI: 0.08, 0.54; P = 0.001), remnant gastritis (OR 0.18, 95%CI: 0.11, 0.29; P < 0.00?001) and re?ux esophagitis (OR 0.48, 95%CI: 0.26, 0.89; P = 0.02). However, this reconstruction method was found to be associated with a longer operation time (WMD 31.30, 95%CI: 12.99, 49.60; P = 0.0008).CONCLUSION: This systematic review point towards some clinical advantages that are rendered by R-Y compared to B-I?reconstruction post DG. However there is a need for further adequately powered, well-designed RCTs comparing the same.

Comparison between uncut Roux-en-Y and Roux-en-Y reconstruction after distal gastrectomy for gastric cancer: A meta-analysis

AIM To compare uncut Roux-en-Y(U-RY) gastrojejunostomy with Roux-en-Y(RY) gastrojejunostomy after distal gastrectomy(DG) for gastric cancer.METHODS A literature search was conducted in Pubmed, Embase, Web of Science, Cochrane Library, Science Direct, Chinese National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database to identify studies comparing U-RY with RY after DG for gastric cancer until the end of December 2017. Pooled odds ratio or weighted mean difference with 95% confidence interval was calculated using either fixed-or random-effects models. Perioperative outcomes such as operative time, intraoperative blood loss, and hospital stay; postoperative complications such as anastomotic bleeding, stricture and ulcer, reflux gastritis/esophagitis, delayed gastric emptying, and Roux stasis syndrome; and postoperative nutritional status(serum hemoglobin, total protein, and albumin levels) were the main outcomes assessed. Metaanalyses were performed using RevM an 5.3 software.RESULTS Two randomized controlled trials and four nonrandomized observational clinical studies involving 403 and 488 patients, respectively, were included. The results of the meta-analysis showed that operative time [weighted mean difference(WMD):-12.95; 95%CI:-22.29 to-3.61; P = 0.007] and incidence of reflux gastritis/esophagitis(OR: 0.40; 95%CI: 0.20-0.80; P = 0.009), delayed gastric emptying(OR: 0.29; 95%CI: 0.14-0.61; P = 0.001), and Roux stasis syndrome(OR: 0.14; 95%CI: 0.04-0.50; P = 0.002) were reduced; and the level of serum albumin(WMD: 0.71; 95%CI: 0.24-1.19; P = 0.003) was increased in patients undergoing U-RY reconstruction compared with those undergoing RY reconstruction. No differences were found with respect to intraoperative blood loss, hospital stay, anastomotic bleeding, anastomotic stricture, anastomotic ulcer, the levels of serum hemoglobin, and serum total protein. CONCLUSION U-RY reconstruction has some clinical advantages over RY reconstruction after DG.

The F5 gene predicts poor prognosis of patients with gastric cancer by promoting cell migration identified using a weighted gene co-expression network analysis

Distal gastric cancer(DGC)is a subgroup of gastric cancer(GC),which has different molecular characteristics from proximal gastric cancer(PGC).These differences result in different overall survival(OS)rates;however,data pertaining to the survival rate in PGC or DGC are contradictory.This suggests that the location of GC is not the unique cause of the different survival rates,while the molecular characteristics might be more important factors determining the prognosis of DGC.Therefore,the aim of this study was to discover key prognostic factors in DGC using bioinformatic methods and to explore the potential molecular mechanism.The Cancer Genome Atlas(TCGA)public database was employed to screen data relating to DGC,and we conducted a weighted gene co-expression network analysis(WGCNA)on DGC patient samples to establish co-expression modules.High-weight genes(hub genes)in a dominant color module were identified.In vitro experiments and gene set enrichment analyses(GSEA)were carried out to elucidate the potential molecular mechanism.In this study,139 DGC samples were enrolled to perform a co-expression analysis.According to the correlation between gene modules and clinical characteristics,the royal blue module related to stage M of DGC was screened,and a survival analysis was conducted to show that highcoagulation-factor V(F5)expression was related to the short OS of patients with GC.In vitro experiments confirmed that F5 could promote the migration of GC cells.GSEA suggested that F5 might have affected the prognosis of GC by modulating the activities of the Wnt and/or the TGF-βsignaling pathways.Our results indicated that high F5 expression predicts poor prognosis of patients with DGC,and it functions probably by promoting cell migration through the Wnt and/or the TGF-βsignaling pathways.

Strategies for gastric cancer in the modern era

Gastric cancer is one of the most common neoplasms in Japan, and it is also the second leading cause of cancer-related deaths worldwide. Nowadays, infection with Helicobacter pylori (H. pylori) is a known risk factor for the development of gastric cancer. Therefore, gastric cancer should be considered as an infectious disease, and in fact, prophylactic eradication of H. pylori may prevent the development of metachronous gastric carcinoma. Before the role of H. pylori was understood, a different approach was used. Recently even after the cancer has developed, some newer therapeutic approaches have been pursued. These newer treatments have been summarized as "minimally invasive therapies" and use endoscopic or laparoscopic techniques. In addition, robotic approaches are being developed that seem to hold a great potential to change the surgical approach. Since basic understanding and treatment of the disease have both changed signif icantly over the last decade, we present a review of current advances in gastric cancer research and therapy.

Roux-en-Y reconstruction does not require gastric decompression after radical distal gastrectomy

AIM: To determine whether routine nasogastric (NG) decompression benefitted patients undergoing radical gastric surgery. METHODS: Between January 1998 and December 2008, 519 patients who underwent distal gastrectomy for gastric cancer were retrospectively divided into 2 time-period cohorts; those treated with Billroth Ⅱ (BⅡ) reconstruction in the first 6 years and those with Roux-en-Y (RY) reconstruction in the last 5 years. In the latter group, the patients were further divided into 2 subgroups; with and without nasogastric decompression.RESULTS: Postoperatively, there were no significant differences in the number of anastomotic leaks between the 3 groups. In the tubeless RY group, time to semiliquid diet was significantly shorter than in the other 2 groups (4.4 d ± 1.4 d vs 7.2 d ± 1.3 d and 5.9 d ± 1.2 d, P = 0.005). The length of postoperative stay was significantly increased in patients with BⅡ reconstruction compared with patients with RY reconstruction with/without NG decompression (15.4 d ± 4.3 d in BⅡ group vs 12.6 d ± 3.1 d in decompressed RY and 11.4 d ± 3.4 d in the tubeless RY group, P = 0.035). The postoperative pneumonia rate was lowest in the tubeless group and highest in the BⅡ group (1.4% vs 4.6%, P = 0.01). Severe sore throat was noted in 59 (20.7%) members of the BⅡ group, 18 (17.4%) members of the decompressed RY group and 6 (4.2%) members of the tubeless RY group. Fewer patients in the tubeless group complained of severe sore throat (P = 0.001). CONCLUSION: This study provides support for abandoning routine NG decompression in patients undergoing subtotal gastrectomy with Roux-en-Y gastrojejunostomy.

Surgical resection of gastric stump cancer following proximal gastrectomy for adenocarcinoma of the esophagogastric junction

BACKGROUND Proximal gastrectomy(PG) is performed widely as a function-preserving operation for early gastric cancer located in the upper third of the stomach and is an important function-preserving approach for esophagogastric junction(EGJ)adenocarcinoma. The incidence of gastric stump cancer(GSC) after PG is increasing. However, little is known about the GSC following PG because very few studies have been conducted on the disease.AIM To clarify clinicopathologic features, perioperative complications, and long-term survival rates after the resection of GSC following PG.METHODS Data for patients with GSC following PG for adenocarcinoma of the EGJ diagnosed between January 1998 and December 2016 were retrospectively reviewed. Multivariate analysis was performed to identify factors associated with overall survival(OS). GSC was defined in accordance with the Japanese Gastric Cancer Association.RESULTS A total of 35 patients were identified. The median interval between the initial PGand resection of GSC was 4.9(range 0.7-12) years. In 21 of the 35 patients, the tumor was located in a nonanastomotic site of the gastric stump. Total gastrectomy was performed in 27 patients; the other 8 underwent partial gastrectomy. Postoperative complications occurred in 6 patients(17.1%). The tumor stage according to the depth of tumor invasion was T1 in 6 patients, T2 in3 patients, T3 in 9 patients, and T4 in 17 patients. Lymph node metastasis was observed in 18 patients. Calculated 1-, 3-, and 5-year OS rates were 86.5%, 62.3%,and 54.2%, respectively. Multivariate analysis showed advanced T stage to be associated with OS.CONCLUSION This study reveals the characteristics of GSC following PG for adenocarcinoma of the EGJ and suggests that a surgical approach can lead to a satisfactory outcome.

术前术后癌胚抗原差值对胃癌患者腹腔镜辅助远端胃癌根治术后复发的影响

目的分析术前、术后癌胚抗原(CEA)差值对胃癌患者腹腔镜辅助远端胃癌根治术(LADG)后复发的影响。方法前瞻性分析,纳入2020年1月至2021年6月安阳市人民医院收治的110例接受LADG治疗的胃癌患者为研究对象,随访2 a,根据2 a内复发情况分为复发组和未复发组。收集患者临床资料及术前1 d、术后1个月血清CEA水平,并计算其差值,分析CEA差值对胃癌患者LADG术后复发的影响。结果110例胃癌患者LADG术后2 a复发41例(37.27%);复发组TNM分期Ⅲ期患者占比高于未复发者(P<0.05);两组患者术前CEA比较,差异无统计学意义(P>0.05),复发组术后CEA、CEA差值高于未复发组(P<0.05);经点二列相关性分析,CEA差值与胃癌患者LADG术后复发呈负相关(r=-0.369,P<0.01);绘制受试者工作特征(ROC)曲线,结果显示,CEA差值预测LADG术后复发的曲线下面积(AUC)为0.715,具有一定预测价值。结论胃癌患者LADG术后复发情况与术前、术后血清CEA差值存在密切关系,术前、术后血清CEA差值对患者术后复发具有一定预测价值。

加速康复外科干预在腹腔镜远端胃癌根治术患者中的应用效果

目的 探讨加速康复外科干预在腹腔镜远端胃癌根治术患者中的应用效果。方法 依据干预方式的不同将80例胃癌患者分为常规组(n=38)和加速康复组(n=42),两组患者均接受腹腔镜远端胃癌根治术治疗,常规组患者接受常规干预,加速康复组患者接受加速康复外科干预。比较两组患者术后恢复指标、心理状态[焦虑自评量表(SAS)、抑郁自评量表(SDS)]、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]、并发症发生情况。结果 加速康复组患者初次肠鸣音恢复时间、初次经口进食时间、初次下床活动时间、引流管留置时间及住院时间均明显短于常规组,差异均有统计学意义(P﹤0.01)。干预后,两组患者SDS、SAS评分均低于本组干预前,EORTC QLQ-C30各维度评分均高于本组干预前,加速康复组患者SDS、SAS评分均低于常规组,EORTC QLQ-C30各维度评分均高于常规组,差异均有统计学意义(P﹤0.05)。加速康复组患者并发症总发生率为7.14%,明显低于常规组患者的28.95%,差异有统计学意义(P﹤0.01)。结论 加速康复外科干预可加快腹腔镜远端胃癌根治术患者康复进程,改善患者心理状态并提高生活质量,降低并发症发生率。

腹腔镜下远端胃癌切除后消化道不同重建方式对患者预后影响分析

目的:探究腹腔镜下远端胃癌切除后消化道不同重建方式对患者预后的影响。方法:回顾性分析107例腹腔镜下远端胃癌切除后消化道重建患者的临床资料,术后均随访1年。根据患者消化道重建方式不同分为Ⅰ组(n=30)、II组(n=28)和R组(n=49),Ⅰ组采取Billroth-Ⅰ式吻合;Ⅱ组患者采取Billroth-Ⅱ式联合布朗吻合;R组患者采取Roux-en-Y吻合。探究各组围术期情况,比较各组术后3周内及术后1年时并发症发生情况。结果:Ⅰ组患者手术时间低于Ⅱ组及R组(P<0.05);各组患者术后3周内并发症发生率比较,差异均无统计学意义(P>0.05);术后1年,R组患者胆汁反流、反流性胃炎发生率低于Ⅰ组及Ⅱ组(P<0.05)。结论:Billroth-Ⅰ式吻合有助于缩短手术时间,但Roux-en-Y吻合在术后远期效果更具优势。

GATA结合蛋白3和粘蛋白1在近端和远端胃癌组织中的表达及临床意义

目的探究GATA结合蛋白3(GATA3)和粘蛋白1(MUC1)在近端胃癌(PGC)和远端胃癌(DGC)组织中的表达及临床意义。方法收集孝感市中心医院2014年2月至2016年3月收治的121例胃癌患者经手术切除的胃癌组织及癌旁组织标本,根据肿瘤发生位置将患者分为PGC组(n=62)和DGC组(n=59),采用实时荧光定量PCR检测两组胃癌组织及癌旁组织中GATA3和MUC1的表达水平;免疫组织化学法检测GATA3和MUC1在各样本中的阳性表达情况,分析GATA3、MUCI与PGC和DGC临床病理特征的关系;Pearson法分析PGC和DGC胃癌组织中GATA3和MUC1表达相关性;Kaplan-Meier曲线分析GATA3和MUC1表达与两组患者5年生存率的关系。结果两组胃癌组织中GATA3和MUC1的表达水平及阳性表达率均高于两组癌旁组织(P<0.05),且PGC组胃癌组织中GATA3、MUCI的表达水平及阳性表达率均明显高于DGC组胃癌组织(P<0.05);两组胃癌组织中GATA3和MUC1的表达呈显著正相关(P<0.05);两组胃癌组织中GATA3和MUC1阳性表达水平与肿瘤TNM分期、淋巴结转移、分化程度以及浸润程度有关(P<0.05);而与患者年龄、性别及肿瘤大小无关(P>0.05),两组GATA3和MUC1阳性表达者的5年生存率低于阴性表达者(P<0.05)。结论GATA3和MUC1在PGC和DGC患者胃癌组织中的表达水平显著增加,且二者的表达与患者临床病理特征及预后有关。

胃良性疾病患者行远端胃切除术后发生残胃癌和食管癌的危险因素分析

目的:探讨胃良性疾病患者行远端胃切除术后残胃癌和食管癌发生的相关危险因素。方法:回顾性分析2010年01月01日至2018年01月01日因胃良性疾病在我院行远端胃切除术的患者的病历资料,采用单因素分析和多因素logistic回归模型确定术后残胃癌和食管癌发生的独立危险因素,并建立远端胃切除术后食管癌、残胃癌发生风险的预测模型。结果:共纳入301例患者,残胃癌患者占11.96%,平均年龄(67.83±9.14)岁,其中进展期患者占83.33%,且只有55.56%的患者有手术机会,残胃癌多见于残胃体及吻合口。5.00%的患者发生了食管癌,平均年龄(68.00±8.73)岁,多见于食管下1/3段,均为进展期,且80.00%失去了手术机会。单因素和二元logistic回归分析显示,年龄≥65岁、手术间隔≥10年和胆汁反流是残胃癌的独立危险因素,年龄≥65岁和胆汁反流是食管癌的独立危险因素。将残胃癌和食管癌发生风险分为低危、中危、高危组,残胃癌在各组发生率分别为1.72%、8.62%、28.99%(P<0.001),食管癌分别为0.70%、4.88%、13.16%(P<0.001)。结论:年龄≥65岁、手术间隔≥10年的因胃良性疾病行远端胃切除术后的患者,建议密切进行胃镜随访。如发现胆汁反流,应仔细检查食管下1/3段、残胃体及吻合口。

达芬奇机器人系统与腹腔镜远端胃癌根治术近期疗效比较

目的比较达芬奇机器人系统与腹腔镜远端胃癌根治术的近期疗效。方法回顾性选取2021年11月至2024年2月宁波大学附属第一医院收治的胃窦、胃角癌患者200例,均择期行远端胃癌根治术。其中98例患者行达芬奇机器人手术治疗,为机器人组;另102例患者行腹腔镜手术治疗,为腹腔镜手术组。比较两组患者围术期指标、术后并发症发生情况。结果两组患者手术时间、术后住院时间比较差异均无统计学意义(均P>0.05)。与腹腔镜组比较,机器人组患者术中出血量较少,术后首次排气时间较短,但手术费用较高,差异均有统计学意义(均P<0.05)。机器人组患者术后并发症发生率低于腹腔镜组(2.04%比8.82%,P<0.05)。结论针对胃癌患者实施远端胃癌根治术,相较于腹腔镜手术,采用达芬奇机器人系统手术的出血量少,术后患者恢复排气时间短,并发症少。

单孔+1孔对比传统多孔3D腹腔镜手术治疗进展期远端胃癌的近期疗效回顾性研究

目的对比单孔+1孔3D腹腔镜手术(SILS+1)与传统多孔3D腹腔镜手术(CLS)对进展期远端胃癌患者的近期疗效差异。方法回顾性分析2021年3月至2022年11月我院胃肠外科收治的245例进展期远端胃癌患者资料,按照手术方式的不同分为CLS组(n=125)和SILS+1组(n=120例),对比分析临床资料及指标包括:基线资料、手术时间、术中失血量及输血量、皮下气肿发生率、中转开腹情况、切除淋巴结总数、切缘阴性率、术后疼痛评分(VAS)、切口美容评分、术后肠内外营养时间、术后住院时间、围术期并发症发生率、总费用等。结果两组患者术前的年龄、性别、体质指数(BMI)、肿瘤术前分期、既往基础病史(高血压、糖尿病、COPD、冠心病、腹部手术史)、肿瘤位置及是否合并幽门梗阻方面等基线指标相比较,差异均无统计学意义(P>0.05)。SILS+1组切口美容评分SCAR更高[(2.10±0.40)分vs.(3.29±0.51)分,P<0.05],术中失血量更少[(94.29±107.65)ml vs.(126.64±104.58)ml,P<0.05],术后胃肠道功能恢复更快[(2.59±0.56)d vs.(2.90±0.50)d,P<0.05]。SILS+1组手术耗时更长[(231.21±40.58)min vs.(203.66±54.78)min],气管插管时间也更长[(273.00±48.16)min vs.(249.22±62.72)min],但是其术中切除淋巴结总数更为彻底,切除数量更多[(28.14±12.02)vs.(24.14±11.53)],差异均有统计学意义(P<0.05)。SILS+1组患者术后第1天、术后第2天、术后第4天VAS评分较CLS组更低,差异有统计学意义(P<0.05)。两组患者肿瘤切缘均为阴性,在术中输血、中转开腹情况、皮下气肿发生率方面差异无统计学意义(P>0.05)。两组患者在术后3天的腹腔引流量、肠内外营养时间、住院时长和住院费用上并无差异(P>0.05)。在术后并发症方面,SILS+1组出现4例深静脉血栓事件、CLS组出现5例,两组中均出现1例全身炎症反应综合征,差异无统计学意义(P>0.05),而SILS+1组肺部感染、腹腔感染、切口感染、吻合口瘘、术后出血、肠梗阻等不良事件的发生率要低于CLS组,差异有统计学意义(P<0.05)。结论就围手术期并发症及术后早期恢复指标而言,SILS+1治疗进展期远端胃癌的近期疗效优于CLS,但SILS+1手术时间略长于CLS,SILS+1治疗进展期远端胃癌的价值亟待高质量的多中心随机对照试验进一步研究。

Uncut Roux-en-Y吻合与Billroth Ⅱ+Braun吻合在腹腔镜远端胃癌根治术中的疗效比较

目的评价腹腔镜远端胃癌根治术Uncut Roux-en-Y、BillrothⅡ+Braun这两类消化道重建途径的临床效果.方法回顾性分析江苏省苏北人民医院胃肠中心2020年1月—2022年4月治疗的102名腹腔镜远端胃癌根治术(LDG)病人的临床资料.其中42人采用Uncut Roux-en-Y吻合术,被归入URY组,60人采用BillrothⅡ联合Braun吻合术,被归入B2B组.对比两组研究对象的基本信息、围手术期相关参数、术后近期并发症与营养情况,以及术后12个月胃镜检查结果,同时采用QLQ-STO 22量表对其术后生活质量展开评估.结果两组皆顺利完成LDG手术,无1例中转开腹与围术期死亡情况.两组在手术用时、吻合时间、术中出血量、术后首次排气时间、进食流质时间、拔除引流管时间、术后住院天数上,差异无统计学意义(P>0.05).两组在术后近期并发症(含吻合口瘘、十二指肠残端瘘、切口感染、肠梗阻等)发生率上,差异无统计学意义(P>0.05).随访1年,URY组1例患者出现肝转移;B2 B组2例出现肿瘤复发,其中1例为肝转移,另1例并发腹腔广泛转移死亡.术后1年91例完成胃镜检查,其中URY组37例,B2 B组54例.URY组出现胃潴留5例(13.5%),B2 B组18例(33.3%),差异有统计学意义(χ^(2)=4.567,P=0.033);发生胆汁反流分别有3例(8.1%)、16例(29.6%),差异有统计学意义(χ^(2)=6.156,P=0.013);发生反流性胃炎分别为1例(2.7%)、12例(22.2%),差异有统计学意义(χ^(2)=6.832,P=0.009);发生反流性食管炎分别为1例(2.7%)、3例(5.6%),差异无统计学意义(χ^(2)=0.017,P=0.895).术后1年评估病人营养情况,两组血淋巴细胞计数(LC)、血红蛋白(Hb)、总蛋白(TP)、血清白蛋白(Alb)、预后营养指数(PNI)等指标比较,无明显统计学差异(P>0.05).术后1年64例完成胃癌(GC)病人生活质量调查问卷(QLQ-STO 22),URY组28例,B2B组36例.结果显示与B2B组比较,URY组减少了反流,差异有统计学意义(P<0.05).结论Uncut Roux-en-Y吻合术减少了胃潴留、胆汁反流和反流性胃炎的发生,改善了患者的生活质量.Uncut Roux-en-Y吻合术途径在LDG消化道重建方面为理想之选.

腹腔镜远端胃癌根治术后不同方式吻合对术后胃食管反流的影响对比研究

目的研究腹腔镜远端胃癌根治术后使用两种不同的方式进行吻合对术后胃食管反流的影响。方法回顾性分析2019年1月-2022年12月本院收治的68例胃癌患者,随机分为两组,对两组患者进行腹腔镜远端胃癌根治术,观察组(n=35)患者进行Uncut Roux-en-Y吻合,对照组(n=33)患者进行B-Ⅱ+Braun吻合。观察两组相关指标,比较两组术后胃食管反流情况、术后营养状态以及术后产生胆汁反流、吻合口瘘、创面感染、残胃炎的患者例数。结果观察组胃肠功能恢复时间比对照组短(P<0.05);观察组GerdQ总评分均低于对照组(P<0.05);观察组术后1个月血红蛋白、白蛋白水平均高于对照组(P<0.05);观察组术后并发症低于对照组(P<0.05)。结论腹腔镜远端胃癌根治术后Uncut Roux-en-Y吻合的疗效较好,可以改善患者术后胃食管反流、营养状态,且并发症也较少。

毕Ⅱ式联合Braun与单纯毕Ⅱ式吻合在腹腔镜远端胃癌根治术中疗效比较的Meta分析

目的系统评价BillrothⅡ式与BillrothⅡ式联合Braun吻合重建术在腹腔镜远端胃癌根治术中的临床疗效差异。方法计算机检索CNKI、VIP、万方数据库、PubMed、Embase、Web of Science等,收集国内外公开发表关于两种消化道重建方式在腹腔镜远端胃癌根治术中比较的临床应用研究。检索时限为2000年1月至2022年10月。对纳入的临床研究进行质量评价及数量提取,并采用Cochrane协作网提供的RevMan5.3统计软件进行Meta分析。结果共纳入9项符合标准的研究,共1483例患者。Meta分析结果显示:在腹腔镜远端胃癌根治术中使用单纯BillrothⅡ式吻合手术时间及消化道重建时间短、术中出血量少,但使用BillrothⅡ联合Braun吻合住院时间短、近期总并发症少、远期反流性疾病少、远期营养状况好,差异均有统计学意义(P<0.05)。而淋巴结清扫数量、首次排气排便时间及部分短期并发症,差异无统计学意义(P>0.05)。结论腹腔镜远端胃癌根治术中,与单纯BillrothⅡ吻合相比,应用BillrothⅡ式联合Braun重建消化道,虽延长手术时间并增加术中出血量,但能减少患者术后近、远期并发症,减少术后住院时间,改善患者远期营养状况,临床应用具有一定优势。

腹腔镜远端胃癌根治术中非离断Roux-en-Y吻合治疗胃癌的临床疗效及其对血清肿瘤因子水平的临床疗效

目的探讨腹腔镜远端胃癌根治术中非离断Roux-en-Y吻合治疗胃癌的临床疗效及其对血清肿瘤因子水平的影响。方法选取2020年1月至2023年3月该院收治的120例胃癌患者作为研究对象,采用随机数字表法分为治疗A组和治疗B组,每组60例。治疗A组进行腹腔镜远端胃癌根治术Bill-rothⅡ+Braun吻合治疗,治疗B组进行腹腔镜远端胃癌根治术非离断Roux-en-Y吻合治疗。观察并比较两组干预后的术中及术后情况、并发症发生情况、术后1年胃镜检查情况、术后生活质量、血清肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)及糖类抗原125(CA125)]及炎症因子水平[白细胞介素6(IL-6)、C-反应蛋白(CRP)水平及白细胞计数(WBC)]。结果两组手术时长、术中出血量、术后排气时长、胃管留置时长、进流食时长、引流管留置时长、术后住院时长比较,差异均无统计学意义(P>0.05)。两组术后总健康状况、功能领域、症状领域生活质量评分比较,差异均无统计学意义(P>0.05)。干预后治疗A组出现食物潴留18例,残胃炎17例,胆汁反流1例,总发生率为60.00%(36/60);治疗B组出现食物潴留5例,残胃炎4例,胆汁反流0例,总发生率为15.00%(9/60)。两组术后1年胃镜检查情况比较,差异有统计学意义(χ^(2)=25.92,P<0.05)。两组术后CEA、CYFRA21-1及CA125水平均低于术前,且治疗B组CEA、CYFRA21-1及CA125水平均低于治疗A组,差异均有统计学意义(P<0.05)。两组术后IL-6、CRP水平及WBC均高于术前,且治疗B组IL-6、CRP水平及WBC均低于治疗A组,差异均有统计学意义(P<0.05)。两组纳入患者在治疗后均无严重不良并发症。治疗A组出现腹腔感染1例,腹腔出血2例,吻合口狭窄1例,十二指肠残端漏3例,其不良并发症的总发生率为11.67%(7/60);治疗B组出现腹腔感染3例,腹腔出血0例,吻合口狭窄1例,十二指肠残端漏1例,其不良并发症的总发生率为8.33%(5/60)。两组并发症总发生率比较,差异无统计学意义(χ^(2)=0.100,P>0.05)。结论腹腔镜远端胃癌根治术非离断Roux-en-Y吻合治疗胃癌患者的临床疗效更为显著,可有效改善患者的血清肿瘤标志物水平,可减轻炎症因子水平,降低不良并发症发生率,值得推广。